AxoGen (LT3) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LT3 Analyst Ratings

Strong Buy

12 Buy

0 Hold

0 Sell

Based on 12 analysts giving stock ratings to

AxoGen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LT3 Stock 12 Month Forecast

Average Price Target

€47.86

▲(9.57% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for AxoGen in the last 3 months. The average price target is €47.86 with a high forecast of €51.73 and a low forecast of €42.81. The average price target represents a 9.57% change from the last price of €43.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"€13","52":"€52","22.75":"€22.8","32.5":"€32.5","42.25":"€42.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51.7261371,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€51.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.86154065,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€47.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.8078376,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€42.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,22.75,32.5,42.25,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.34,37.52354900769231,38.70709801538462,39.89064702307692,41.07419603076924,42.25774503846154,43.44129404615385,44.624843053846156,45.80839206153846,46.991941069230776,48.17549007692308,49.35903908461539,50.542588092307696,{"y":51.7261371,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.34,37.22627235769231,38.112544715384615,38.99881707307693,39.885089430769234,40.77136178846154,41.657634146153846,42.54390650384616,43.430178861538465,44.31645121923077,45.20272357692308,46.08899593461538,46.975268292307696,{"y":47.86154065,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.34,36.837525969230775,37.33505193846154,37.83257790769231,38.330103876923076,38.82762984615385,39.32515581538462,39.82268178461538,40.320207753846155,40.81773372307693,41.31525969230769,41.81278566153846,42.31031163076923,{"y":42.8078376,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.4,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.84,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.35,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.04,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.34,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€51.73

Average Price Target€47.86

Lowest Price Target€42.81

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mike Kratky

Leerink Partners

€46.38

Buy

6.17%

Upside

Reiterated

10/12/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and AxoGen (NASDAQ: AXGN)

Travis Steed

Bank of America Securities

€46.38

Buy

6.17%

Upside

Initiated

10/12/26

Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Gilead Sciences (GILD)

Christopher Pasquale

Barclays

€49.05

Buy

12.30%

Upside

Initiated

10/06/26

AxoGen initiated with an Overweight at BarclaysAxoGen initiated with an Overweight at Barclays

Caitlin Roberts

Canaccord Genuity

€49.05

Buy

12.30%

Upside

Reiterated

10/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Frank Takkinen

Lake Street

€49.05

Buy

12.30%

Upside

Reiterated

10/05/26

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (NASDAQ: XERS) and AxoGen (NASDAQ: AXGN)

Larry Biegelsen

Wells Fargo

€42.81

Buy

-2.00%

Downside

Reiterated

10/02/26

Wells Fargo Sticks to Its Buy Rating for AxoGen (AXGN)

Ravi Misra

Truist Financial

€53.51→€47.27

Buy

8.21%

Upside

Reiterated

10/01/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Michael Sarcone

Jefferies

€49.05

Buy

12.30%

Upside

Reiterated

09/29/26

Jefferies Reaffirms Their Buy Rating on AxoGen (AXGN)

Jayson Bedford

Raymond James

€42.81→€47.27

Buy

8.21%

Upside

Reiterated

09/25/26

AxoGen price target raised to $53 from $48 at Raymond JamesAxoGen price target raised to $53 from $48 at Raymond James

Anthony Petrone

Mizuho Securities

€51.73

Buy

18.42%

Upside

Reiterated

07/31/26

Analysts' Top Healthcare Picks: Dexcom (DXCM), AxoGen (AXGN)

Yi Chen

H.C. Wainwright

€44.59→€47.27

Buy

8.21%

Upside

Reiterated

07/30/26

AxoGen price target raised to $53 from $50 at H.C. WainwrightAxoGen price target raised to $53 from $50 at H.C. Wainwright

David Turkaly

Citizens JMP

€44.59→€49.05

Buy

12.30%

Upside

Reiterated

07/30/26

AxoGen price target raised to $55 from $50 at CitizensAxoGen price target raised to $55 from $50 at Citizens

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mike Kratky

Leerink Partners

€46.38

Buy

6.17%

Upside

Reiterated

10/12/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and AxoGen (NASDAQ: AXGN)

Travis Steed

Bank of America Securities

€46.38

Buy

6.17%

Upside

Initiated

10/12/26

Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Gilead Sciences (GILD)

Christopher Pasquale

Barclays

€49.05

Buy

12.30%

Upside

Initiated

10/06/26

AxoGen initiated with an Overweight at BarclaysAxoGen initiated with an Overweight at Barclays

Caitlin Roberts

Canaccord Genuity

€49.05

Buy

12.30%

Upside

Reiterated

10/05/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Frank Takkinen

Lake Street

€49.05

Buy

12.30%

Upside

Reiterated

10/05/26

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (NASDAQ: XERS) and AxoGen (NASDAQ: AXGN)

Larry Biegelsen

Wells Fargo

€42.81

Buy

-2.00%

Downside

Reiterated

10/02/26

Wells Fargo Sticks to Its Buy Rating for AxoGen (AXGN)

Ravi Misra

Truist Financial

€53.51→€47.27

Buy

8.21%

Upside

Reiterated

10/01/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Michael Sarcone

Jefferies

€49.05

Buy

12.30%

Upside

Reiterated

09/29/26

Jefferies Reaffirms Their Buy Rating on AxoGen (AXGN)

Jayson Bedford

Raymond James

€42.81→€47.27

Buy

8.21%

Upside

Reiterated

09/25/26

AxoGen price target raised to $53 from $48 at Raymond JamesAxoGen price target raised to $53 from $48 at Raymond James

Anthony Petrone

Mizuho Securities

€51.73

Buy

18.42%

Upside

Reiterated

07/31/26

Analysts' Top Healthcare Picks: Dexcom (DXCM), AxoGen (AXGN)

Yi Chen

H.C. Wainwright

€44.59→€47.27

Buy

8.21%

Upside

Reiterated

07/30/26

AxoGen price target raised to $53 from $50 at H.C. WainwrightAxoGen price target raised to $53 from $50 at H.C. Wainwright

David Turkaly

Citizens JMP

€44.59→€49.05

Buy

12.30%

Upside

Reiterated

07/30/26

AxoGen price target raised to $55 from $50 at CitizensAxoGen price target raised to $55 from $50 at Citizens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ONCBeOne Medicines

OVIDOvid Therapeutics

ASNDAscendis Pharma

QNCXQuince Therapeutics

EHCEncompass Health

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AxoGen

3 Months

Mike KratkyLeerink Partners

Success Rate

9/13 ratings generated profit

Average Return

+21.84%

Copying Mike Kratky's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +21.84% per trade.

1 Year

Mike KratkyLeerink Partners

Success Rate

13/13 ratings generated profit

Average Return

+141.87%

Copying Mike Kratky's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +141.87% per trade.

2 Years

Mike KratkyLeerink Partners

Success Rate

13/13 ratings generated profit

Average Return

+247.54%

Copying Mike Kratky's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +247.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LT3 Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LT3 has received 15 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. LT3 average Analyst price target in the past 3 months is 47.86.

Each month's total comprises the sum of three months' worth of ratings.

LT3 Financial Forecast

LT3 Earnings Forecast

Next quarter’s earnings estimate for LT3 is €0.12 with a range of €0.07 to €0.14. The previous quarter’s EPS was €0.11. LT3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year LT3 has Performed in-line its overall industry.

LT3 Sales Forecast

Next quarter’s sales forecast for LT3 is €65.31M with a range of €64.21M to €66.04M. The previous quarter’s sales results were €62.19M. LT3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year LT3 has Performed in-line its overall industry.

LT3 Stock Forecast FAQ

What is DE:LT3’s average 12-month price target, according to analysts?

Based on analyst ratings, AxoGen’s 12-month average price target is 47.86.

What is DE:LT3’s upside potential, based on the analysts’ average price target?

AxoGen has 9.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AxoGen a Buy, Sell or Hold?

AxoGen has a consensus rating of Strong Buy, which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.

What is AxoGen’s share price target?

The average share price target for AxoGen is 47.86. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €51.73 ,and the lowest forecast is €42.81. The average share price target represents 9.57% Increase from the current price of €43.68.

What do analysts say about AxoGen?

AxoGen’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of AxoGen?

To buy shares of DE:LT3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

AxoGen (LT3) Stock Forecast & Price Target

LT3 Analyst Ratings

LT3 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AxoGen

LT3 Analyst Recommendation Trends

LT3 Financial Forecast

LT3 Earnings Forecast

LT3 Sales Forecast

LT3 Stock Forecast FAQ

Detailed List of Analyst Forecasts